Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma by Auvray, Marie et al.
European Journal of Cancer 119 (2019) 200e201Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer.comErratumErratum to ‘Second-line targeted therapies after
nivolumab-ipilimumab failure in metastatic renal cell
carcinoma’ [Eur J Cancer 108 (February 2019) 33e40]Marie Auvray a, Edouard Auclin b,c,d, Philippe Barthelemy e, Petri Bono f,
Pirkko Kellokumpu-Lehtinen g, Marine Gross-Goupil h,
Guillermo De Velasco i, Thomas Powles j, Guillaume Mouillet k,
Yann-Alexandre Vano l, Gwenaëlle Gravis m, Loı̈c Mourey n,
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